10-K Filing

ENZON PHARMACEUTICALS, INC. CIK: 727510 FY 2023

Filing Information

Form Type	10-K
Accession Number	`0001410578-24-000245`
Period End Date	20231231
Filing Date	20240320
Fiscal Year	2023
Fiscal Period	FY
XBRL Instance	enzn-20231231x10k_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 49 Income Statement 28 Cash Flow Statement 21 Stockholders Equity 10

Balance Sheet 49 line items

Line Item	Tag	Value	Unit	Period
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$46.98M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$47.01M	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$405.00K	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$331.00K	USD	Point-in-time
Total current assets	`AssetsCurrent`	$47.39M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$47.34M	USD	Point-in-time
Deferred tax asset	`DeferredIncomeTaxAssetsNet`	$359.00K	USD	Point-in-time
Deferred tax asset	`DeferredIncomeTaxAssetsNet`	$202.00K	USD	Point-in-time
Total assets	`Assets`	$47.59M	USD	Point-in-time
Preferred stock, par value (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Total assets	`Assets`	$47.70M	USD	Point-in-time
Preferred stock, par value (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	2.96M	shares	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	2.96M	shares	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$331.00K	USD	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$331.00K	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Accrued expenses and other current liabilities	`AccruedLiabilitiesCurrent`	$93.00K	USD	Point-in-time
Accrued expenses and other current liabilities	`AccruedLiabilitiesCurrent`	$108.00K	USD	Point-in-time
Dividends payable on Series C preferred stock	`DividendsPayableCurrent`	$1.27M	USD	Point-in-time
Dividends payable on Series C preferred stock	`DividendsPayableCurrent`	$1.27M	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	170.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	170.00M	shares	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.71M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	74.21M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	74.21M	shares	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.70M	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	74.21M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	74.21M	shares	Point-in-time
Commitments and contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Preferred stock - $0.01 par value, authorized 2,960,000 shares; no shares issued and outstanding at December 31, 2023 and 2022	`PreferredStockValue`	-	USD	Point-in-time
Preferred stock - $0.01 par value, authorized 2,960,000 shares; no shares issued and outstanding at December 31, 2023 and 2022	`PreferredStockValue`	-	USD	Point-in-time
Common stock - $0.01 par value, authorized 170,000,000 shares; issued and outstanding 74,214,603 shares at December 31, 2023 and 2022	`CommonStockValue`	$742.00K	USD	Point-in-time
Common stock - $0.01 par value, authorized 170,000,000 shares; issued and outstanding 74,214,603 shares at December 31, 2023 and 2022	`CommonStockValue`	$742.00K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapitalCommonStock`	$74.71M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapitalCommonStock`	$73.43M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-72.04M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-70.67M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$4.87M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$3.41M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$3.50M	USD	Point-in-time
Total liabilities, mezzanine equity and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$47.59M	USD	Point-in-time
Total liabilities, mezzanine equity and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$47.70M	USD	Point-in-time

Income Statement 28 line items

Line Item	Tag	Value	Unit	Period
Royalties and milestones, net	`RoyaltyRevenueAndMilestones`	$26.00K	USD	Annual
Total revenues	`Revenues`	$26.00K	USD	Annual
General and administrative	`OtherGeneralAndAdministrativeExpense`	$1.04M	USD	Annual
General and administrative	`OtherGeneralAndAdministrativeExpense`	$1.06M	USD	Annual
Total operating expenses	`OperatingExpenses`	$1.04M	USD	Annual
Total operating expenses	`OperatingExpenses`	$1.06M	USD	Annual
Operating loss	`OperatingIncomeLoss`	$-1.04M	USD	Annual
Operating loss	`OperatingIncomeLoss`	$-1.03M	USD	Annual
Interest and dividend income	`OtherInterestAndDividendIncome`	$646.00K	USD	Annual
Interest and dividend income	`OtherInterestAndDividendIncome`	$2.26M	USD	Annual
Income (loss) before income tax benefit	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$1.22M	USD	Annual
Income (loss) before income tax benefit	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-386.00K	USD	Annual
Income tax benefit	`IncomeTaxExpenseBenefit`	$-200.00K	USD	Annual
Income tax benefit	`IncomeTaxExpenseBenefit`	$-156.00K	USD	Annual
Net Income (Loss)	`NetIncomeLoss`	$1.37M	USD	Annual
Net Income (Loss)	`NetIncomeLoss`	$-186.00K	USD	Annual
Dividends on Series C preferred stock	`PreferredStockDividendsIncomeStatementImpact`	$1.27M	USD	Annual
Dividends on Series C preferred stock	`PreferredStockDividendsIncomeStatementImpact`	$1.27M	USD	Annual
Net income (loss) available to common shareholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$98.00K	USD	Annual
Net income (loss) available to common shareholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-1.46M	USD	Annual
Basic	`EarningsPerShareBasic`	-	USD	Annual
Basic	`EarningsPerShareBasic`	$-0.02	USD	Annual
Diluted	`EarningsPerShareDiluted`	$-0.02	USD	Annual
Diluted	`EarningsPerShareDiluted`	-	USD	Annual
Weighted average number of common shares - basic	`WeightedAverageNumberOfSharesOutstandingBasic`	74.22M	shares	Annual
Weighted average number of common shares - basic	`WeightedAverageNumberOfSharesOutstandingBasic`	74.22M	shares	Annual
Weighted average number of common shares - diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	74.22M	shares	Annual
Weighted average number of common shares - diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	74.22M	shares	Annual

Cash Flow Statement 21 line items

Line Item	Tag	Value	Unit	Period
Net Income (Loss)	`NetIncomeLoss`	$1.37M	USD	Annual
Net Income (Loss)	`NetIncomeLoss`	$-186.00K	USD	Annual
Deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$-157.00K	USD	Annual
Deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$-202.00K	USD	Annual
Decrease in royalty receivable	`IncreaseDecreaseInRoyaltyReceivables`	$-28.00K	USD	Annual
Decrease (increase) in other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$320.00K	USD	Annual
Decrease (increase) in other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$-74.00K	USD	Annual
Increase in accrued expenses and other current liabilities	`IncreaseDecreaseInOtherAccruedLiabilities`	$15.00K	USD	Annual
Increase in accrued expenses and other current liabilities	`IncreaseDecreaseInOtherAccruedLiabilities`	$21.00K	USD	Annual
Net cash provided by (used in) operating activities	`NetCashProvidedByUsedInOperatingActivities`	$1.30M	USD	Annual
Net cash provided by (used in) operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-659.00K	USD	Annual
Preferred stock dividend payments	`PaymentsOfDividendsCommonStock`	$1.27M	USD	Annual
Net cash used in financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-1.27M	USD	Annual
Net increase (decrease) in cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$30.00K	USD	Annual
Net increase (decrease) in cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-659.00K	USD	Annual
Cash and cash equivalents at beginning of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$47.64M	USD	Point-in-time
Cash and cash equivalents at beginning of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$46.98M	USD	Point-in-time
Cash and cash equivalents at beginning of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$47.01M	USD	Point-in-time
Cash and cash equivalents at end of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$47.64M	USD	Point-in-time
Cash and cash equivalents at end of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$46.98M	USD	Point-in-time
Cash and cash equivalents at end of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$47.01M	USD	Point-in-time

Stockholders Equity 10 line items

Line Item	Tag	Value	Unit	Period
Balance at the beginning	`StockholdersEquity`	$4.87M	USD	Point-in-time
Balance at the beginning	`StockholdersEquity`	$3.41M	USD	Point-in-time
Balance at the beginning	`StockholdersEquity`	$3.50M	USD	Point-in-time
Net Income (Loss)	`NetIncomeLoss`	$1.37M	USD	Annual
Net Income (Loss)	`NetIncomeLoss`	$-186.00K	USD	Annual
Preferred stock dividend declared	`DividendsCommonStockStock`	$1.27M	USD	Annual
Preferred stock dividend declared	`DividendsCommonStockStock`	$1.27M	USD	Annual
Balance at the ending	`StockholdersEquity`	$4.87M	USD	Point-in-time
Balance at the ending	`StockholdersEquity`	$3.41M	USD	Point-in-time
Balance at the ending	`StockholdersEquity`	$3.50M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.